Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Study Purpose
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 18 Years and Over |
| Gender | All |
Inclusion Criteria:
- - PHASE II INCLUSION CRITERIA (COMPLETE AS OF 20-MAR-2020) - Pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), larynx, or hypopharynx.
- - Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p16 negative), larynx, or hypopharynx within 63 days prior to registration; Note: patients may have biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection; the gross total resection has to be done within 63 days prior to registration; if, however, patients have ablative resection but shortly recur or are determined to have persisting disease requiring re-resection to achieve gross total resection, then the patient is not eligible.
- - Patients must have at least 1 of the following high-risk pathologic features: extracapsular nodal extension or invasive cancer at the primary tumor resection margin (tumor on ink) - Pathologic stage III or IV HNSCC, including no distant metastases, based upon the following minimum diagnostic workup: - General history and physical examination by a radiation oncologist and/or medical oncologist within 84 days prior to registration; - Examination by an ear nose throat (ENT) or head & neck surgeon prior to surgery; a laryngopharyngoscopy (mirror and/or fiber optic and/or direct procedure), if appropriate, is recommended but not required; intra-operative examination is acceptable documentation.
- - Pre-operative (op) Imaging of the head and neck: A neck computed tomography (CT) (with contrast) or CT/positron emission tomography (PET) (with contrast) and/or an magnetic resonance imaging (MRI) of the neck (T1 with gadolinium and T2) within 84 days prior to surgery; Note: this imaging data (diagnostic pre-operative scan showing gross disease) is to be submitted in Digital Imaging and Communications in Medicine (DICOM) format via TRIAD; the report is to be uploaded into Rave.
- - Chest CT scan (with or without contrast) or CT/PET that includes the chest (with or without contrast) either within 84 days prior to surgery or within 120 days prior to registration; Note: if the CT/PET with or without contrast is done within 84 days prior to surgery, it fulfills the chest imaging requirement.
- - Zubrod performance status of 0-1 within 14 days prior to registration.
- - Age >= 18.
- - Absolute granulocyte count (AGC) >= 1,500 cells/mm^3 (obtained within 14 days prior to registration on study) - Platelets >= 100,000 cells/mm^3 (obtained within 14 days prior to registration on study) - Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable) - Total bilirubin < 2 x institutional upper limit of normal (ULN) within 14 days prior to registration.
- - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x institutional ULN within 14 days prior to registration.
- - Serum creatinine institutional ULN within 14 days prior to registration or; creatinine clearance (CC) >= 50 ml/min within 14 days prior to registration determined by 24-hour collection or estimated by Cockcroft-Gault formula.
- - Negative urine or serum pregnancy test within 14 days prior to registration for women of childbearing potential.
- - The following assessments are required within 14 days prior to registration: sodium (Na), potassium (K), chloride (Cl), glucose, calcium (Ca), magnesium (Mg), and albumin; Note: patients with an initial magnesium < 0.5 mmol/L (1.2 mg/dl) may receive corrective magnesium supplementation but should continue to receive either prophylactic weekly infusion of magnesium and/or oral magnesium supplementation (e.g., magnesium oxide) at the investigator's discretion.
- - Patients with feeding tubes are eligible for the study.
- - Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control.
- - Patient must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for epidermal growth factor receptor (EGFR) analysis and for oropharyngeal cancer patients, human papilloma virus (HPV) analysis.
- - PHASE III: Pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), larynx, or hypopharynx.
- - PHASE III: Patients with oropharyngeal cancer must have p16-negative based on central review prior to Step 2 registration.
- - PHASE III: Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p16 negative), larynx, or hypopharynx within 63 days prior to registration.
- - Note: Patients may have biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection.
- - PHASE III: Patients must have at least 1 of the following high-risk pathologic features: extracapsular nodal extension or invasive cancer at the primary tumor resection margin (tumor on ink or tumor in a final separately submitted margin) - PHASE III: Pathologic stage III or IV HNSCC (American Joint Committee on Cancer [AJCC] 7th edition), including no distant metastases, based upon the following minimum diagnostic workup: - General history and physical examination by a radiation oncologist or medical oncologist within 84 days prior to registration; - Examination by an ENT or head & neck surgeon prior to surgery; a laryngopharyngoscopy (mirror or fiberoptic or direct procedure), if appropriate, is recommended but not required.
- - Pre-op Imaging of the head and neck: A neck CT (with contrast and of diagnostic quality) or PET/CT (with contrast and of diagnostic quality) and/or an MRI of the neck of diagnostic quality (T1 with gadolinium and T2) within 84 days prior to surgery; Note: this imaging data (diagnostic pre-operative scan showing gross disease) is to be submitted in DICOM format via TRIAD.
- - Chest CT scan (with or without contrast) or PET/CT that includes the chest (with or without contrast) either within 84 days prior to surgery or within 120 days prior to registration; Note: If the PET/CT with or without contrast is done within 84 days prior to surgery, it fulfills the chest imaging requirement.
- - PHASE III: Zubrod performance status of 0-1 within 14 days prior to registration.
- - PHASE III: Age >= 18.
- - PHASE III: Leukocytes >= 2,500 cells/mm^3 (obtained within 14 days prior to registration on study) - PHASE III: Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (obtained within 14 days prior to registration on study) - PHASE III: Platelets >= 100,000 cells/mm^3 (obtained within 14 days prior to registration on study) - PHASE III: Hemoglobin >= 8.0 g/dL (Note: The use of transfusion or other intervention to achieve Hgb >= 8.0 g/dL is acceptable) (obtained within 14 days prior to registration on study) - PHASE III: Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =< 3 x institutional ULN may be enrolled) (within 14 days prior to registration) - PHASE III: AST or ALT =< 3 x institutional ULN (within 14 days prior to registration) - PHASE III: Alkaline phosphatase =< 2.5 x institutional ULN (within 14 days prior to registration) - PHASE III: Creatinine clearance (CrCl) >= 50 mL/min within 14 days prior to registration determined by 24-hour collection or estimated by Cockcroft-Gault formula.
- - PHASE III: Patients with feeding tubes are eligible for the study.
- - PHASE III: Negative urine or serum pregnancy test within 14 days prior to registration for women of childbearing potential.
- - PHASE III: All patients must provide study specific informed consent prior to study entry.
- - PHASE III: Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have: - A stable regimen of highly active anti-retroviral therapy (HAART); - No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections; - A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests.
Exclusion Criteria:
- - PHASE II EXCLUSION CRITERIA (COMPLETE AS OF 20-MAR-2020) - Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years); noninvasive cancers (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) are permitted even if diagnosed and treated < 3 years ago.
- - Patients with simultaneous primaries or bilateral tumors are excluded, with the exception of patients with bilateral tonsil cancers or patients with T1-2, N0, M0 resected differentiated thyroid carcinoma, who are eligible.
- - Prior systemic chemotherapy or anti-epidermal growth factor (EGF) therapy for the study cancer; note that prior chemotherapy for a different cancer is allowable.
- - Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
- - Severe, active co-morbidity, defined as follows: - Unstable angina and/or congestive heart failure requiring hospitalization within 6 months prior to registration.
- - Transmural myocardial infarction within 6 months prior to registration.
- - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
- - Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration.
- - Idiopathic pulmonary fibrosis or other severe interstitial lung disease that requires oxygen therapy or is thought to require oxygen therapy within 1 year prior to registration.
- - Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol.
- - Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive; protocol-specific requirements may also exclude immuno-compromised patients.
- - Grade 3-4 electrolyte abnormalities (Common Terminology Criteria for Adverse Events [CTCAE], version [v.
- - Serum calcium (ionized or adjusted for albumin) < 7 mg/dl (1.75 mmol/L) or > 12.5 mg/dl (> 3.1 mmol/L) despite intervention to normalize levels.
- - Glucose < 40 mg/dl (< 2.2 mmol/L) or > 250 mg/dl (> 14 mmol/L) - Magnesium < 0.9 mg/dl (< 0.4 mmol/L) or > 3 mg/dl (> 1.23 mmol/L) despite intervention to normalize levels.
- - Potassium < 3.0 mmol/L or > 6 mmol/L despite intervention to normalize levels.
- - Sodium < 130 mmol/L or > 155 mmol/L despite intervention to normalize levels.
- - Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
- - Prior allergic reaction to cetuximab.
- - PHASE III: Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years) with the following exceptions: T1-2, N0, M0 resected differentiated thyroid carcinoma; Note that noninvasive cancers (For example, carcinoma in situ of the breast, oral cavity, or cervix) are permitted even if diagnosed and treated < 3 years ago.
- - PHASE III: Patients with simultaneous primaries or bilateral tumors are excluded, with the exception of patients with bilateral tonsil cancers or patients with T1-2, N0, M0 resected differentiated thyroid carcinoma, who are eligible.
- - PHASE III: Prior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy (such as anti-EGF therapy), or immune therapy for the study cancer; note that prior chemotherapy for a different cancer is allowable, however, a prior anti-PD-1, anti-PD-L1, or anti-PD-L2 agent is not permitted.
- - PHASE III: Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
- - PHASE III: Severe, active co-morbidity, defined as follows: - Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification; to be eligible for this trial, patients should be class 2B or better within 6 months prior to registration.
- - Transmural myocardial infarction within 6 months prior to registration; - Severe infections within 4 weeks prior to registration including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia; - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration; Note: Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible.
- - Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration; - History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan.
- - Patients with active tuberculosis (TB) are excluded; - Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease; - Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible.
- - Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
- - History of allogeneic bone marrow transplantation or solid organ transplantation.
- - A diagnosis of immunodeficiency: - Acquired immune deficiency syndrome (AIDS) based upon current CDC definition; note: HIV testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
- - Is receiving treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to registration.
- - Note: Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.
- - Note: The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
- - History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
- - Patients with a history of autoimmune hypothyroidism who are asymptomatic and/or are on a stable dose of thyroid replacement hormone are eligible.
- - Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen are eligible.
- - Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: - Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations.
- - Rash must cover less than 10% of body surface area (BSA) - Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%) - No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids) - PHASE III: Grade 3-4 electrolyte abnormalities (CTCAE, v.
- - Serum calcium (ionized or adjusted for albumin) < 7 mg/dL (1.75 mmol/L) or > 12.5 mg/dL (> 3.1 mmol/L) despite intervention to normalize levels; - Glucose < 40 mg/dL (< 2.2 mmol/L) or > 250 mg/dL (> 14 mmol/L); - Magnesium < 0.9 mg/dL (< 0.4 mmol/L) or > 3 mg/dL (> 1.23 mmol/L) despite intervention to normalize levels; - Potassium < 3.0 mmol/L or > 6 mmol/L despite intervention to normalize levels; - Sodium < 130 mmol/L or > 155 mmol/L despite intervention to normalize levels.
- - PHASE III: Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception for up to 5 months from last study treatment; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
- - PHASE III: History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
- - PHASE III: Patients taking bisphosphonate therapy for symptomatic hypercalcemia.
- - PHASE III: Patients requiring treatment with a RANKL inhibitor (e.g. denosumab) for non-oncologic reasons who cannot discontinue it before registration.
- - PHASE III: Patients with known distant metastatic disease are excluded.
- - PHASE III: Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies.
- - PHASE III: Major surgical procedure within 28 days prior to registration or anticipation of need for a major surgical procedure during the course of the study.
- - PHASE III: Administration of a live, attenuated vaccine within 4 weeks prior to registration or anticipation that such a live, attenuated vaccine will be required during the study and for patients receiving atezolizumab, up to 5 months after the last dose of atezolizumab.
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT01810913 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 2/Phase 3 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
National Cancer Institute (NCI) |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Paul M Harari |
| Principal Investigator Affiliation | NRG Oncology |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
NIH, Other |
| Overall Status | Recruiting |
| Countries | Canada, Hong Kong, United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7 |
PRIMARY OBJECTIVES:
- I. To select the better docetaxel-based experimental arm to improve disease-free survival (DFS) over the control arm of radiation and cisplatin.
- II. To determine if the combination of docetaxel-cetuximab and intensity-modulated radiation therapy (IMRT) is superior in terms of overall survival (OS) compared to standard cisplatin and IMRT in the adjuvant treatment of pathologic high risk, human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC).
- III. To determine if the combination of atezolizumab, cisplatin, and IMRT is superior in terms of OS compared to standard cisplatin and IMRT in the adjuvant treatment of pathologic high risk, HPV-negative HNSCC.
- I. To compare disease-free survival (DFS) between each experimental arm and the control arm.
- II. To determine whether each experimental arm improves local-regional disease control and the rate of distant metastasis.
- III. To compare acute toxicity profiles between each experimental arm and the control arm.
- IV. To compare late toxicity profiles at 1, 3, and 5 years after treatment.
- V. To assess long term DFS and OS between each experimental arm and the control arm.
- VI. To compare symptom burden, as measured by the MD Anderson Symptom Inventory - Head and Neck (MDASI-HN) (primary patient reported outcome [PRO]), and quality of life, as measured by the Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&N) (secondary PRO), between each experimental arm and the control arm.
- I. To collect blood and tissue specimens for future translational research.
- - Phase II (Arms 1, 2 or 3) and for Phase III (Arms 1, 3 or 4).
Arms
Experimental: Arm 1 (IMRT, cisplatin)
Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin IV over 1-2 hours once weekly for 6 weeks. Patients undergo collection of blood samples during screening and throughout the study and may undergo CT scans and/or MRI and biopsy as clinically indicated on study.
Experimental: Arm 2 (IMRT, docetaxel)
Patients undergo IMRT as in Arm I and receive concurrent docetaxel IV over 60 minutes once weekly for 6 weeks. Patients undergo CT scans and/or MRI, and collection of blood during follow-up. (CLOSED AS OF 20-MAR-2020)
Experimental: Arm 3 (IMRT, docetaxel, cetuximab)
Patients receive cetuximab IV over 120 minutes on week 1 and over 60 minutes once weekly on weeks 2-7. Patients undergo IMRT as in Arm I and receive concurrent docetaxel once weekly for 6 weeks. Patients undergo collection of blood samples during screening and throughout the study and may undergo CT scans and/or MRI and biopsy as clinically indicated on study.
Experimental: Arm 4 (IMRT, cisplatin, atezolizumab)
Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin IV over 1-2 hours once weekly for 6 weeks. Starting 1 week before IMRT, patients also receive atezolizumab IV over 30-60 minutes every 3 weeks for up to 8 doses (weeks -1, 3, 6, 9, 12, 15, 18, and 21) in the absence of disease progression and unacceptable toxicity. Patients undergo collection of blood samples during screening and throughout the study and may undergo CT scans and/or MRI and biopsy as clinically indicated on study.
Interventions
Drug: - Atezolizumab
Given IV
Procedure: - Biopsy
Undergo biopsy
Procedure: - Biospecimen Collection
Undergo collection of blood
Biological: - Cetuximab
Given IV
Drug: - Cisplatin
Given IV
Procedure: - Computed Tomography
Undergo CT
Drug: - Docetaxel
Given IV
Radiation: - Intensity-Modulated Radiation Therapy
Undergo IMRT
Other: - Laboratory Biomarker Analysis
Correlative studies
Procedure: - Magnetic Resonance Imaging
Undergo MRI
Other: - Quality-of-Life Assessment
Ancillary studies
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Active, not recruiting
Address
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233
Status
Suspended
Address
The Kirklin Clinic at Acton Road
Birmingham, Alabama, 35243
Status
Recruiting
Address
Banner University Medical Center - Tucson
Tucson, Arizona, 85719
Status
Recruiting
Address
University of Arizona Cancer Center-North Campus
Tucson, Arizona, 85719
Status
Active, not recruiting
Address
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Status
Recruiting
Address
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, 95603
Status
Recruiting
Address
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, 91505
Status
Recruiting
Address
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California, 95682
Status
Recruiting
Address
Mercy San Juan Medical Center
Carmichael, California, 95608
Status
Suspended
Address
UC San Diego Health System - Encinitas
Encinitas, California, 92024
Status
Suspended
Address
UC San Diego Moores Cancer Center
La Jolla, California, 92093
Status
Recruiting
Address
Cedars Sinai Medical Center
Los Angeles, California, 90048
Status
Recruiting
Address
Memorial Medical Center
Modesto, California, 95355
Status
Recruiting
Address
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868
Status
Recruiting
Address
Stanford Cancer Institute Palo Alto
Palo Alto, California, 94304
Status
Recruiting
Address
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California, 95661
Status
Recruiting
Address
Sutter Medical Center Sacramento
Sacramento, California, 95816
Status
Suspended
Address
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817
Status
Active, not recruiting
Address
Saint Helena Hospital
Saint Helena, California, 94574
Status
Recruiting
Address
UCSF Medical Center-Mount Zion
San Francisco, California, 94115
Status
Recruiting
Address
UCSF Medical Center-Mission Bay
San Francisco, California, 94158
Status
Recruiting
Address
Mills Health Center
San Mateo, California, 94401
Status
Active, not recruiting
Address
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045
Status
Recruiting
Address
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado, 80304
Status
Recruiting
Address
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, 80907
Status
Recruiting
Address
AdventHealth Porter
Denver, Colorado, 80210
Status
Recruiting
Address
Shaw Cancer Center
Edwards, Colorado, 81632
Status
Suspended
Address
Banner North Colorado Medical Center
Greeley, Colorado, 80631
Status
Recruiting
Address
Rocky Mountain Cancer Centers-Littleton
Littleton, Colorado, 80120
Status
Recruiting
Address
Longmont United Hospital
Longmont, Colorado, 80501
Status
Suspended
Address
Banner McKee Medical Center
Loveland, Colorado, 80539
Status
Recruiting
Address
AdventHealth Parker
Parker, Colorado, 80138
Status
Active, not recruiting
Address
University of Connecticut
Farmington, Connecticut, 06030
Status
Recruiting
Address
Yale University
New Haven, Connecticut, 06520
Status
Recruiting
Address
Smilow Cancer Hospital Care Center - Waterford
Waterford, Connecticut, 06385
Status
Suspended
Address
Helen F Graham Cancer Center
Newark, Delaware, 19713
Status
Suspended
Address
Christiana Care Health System-Christiana Hospital
Newark, Delaware, 19718
Status
Recruiting
Address
George Washington University Medical Center
Washington, District of Columbia, 20037
Status
Active, not recruiting
Address
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, 33442
Status
Recruiting
Address
Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Status
Active, not recruiting
Address
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136
Status
Active, not recruiting
Address
AdventHealth Orlando
Orlando, Florida, 32803
Status
Recruiting
Address
Orlando Health Cancer Institute
Orlando, Florida, 32806
Status
Recruiting
Address
Moffitt Cancer Center
Tampa, Florida, 33612
Status
Recruiting
Address
Emory University Hospital Midtown
Atlanta, Georgia, 30308
Status
Recruiting
Address
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322
Status
Recruiting
Address
Augusta University Medical Center
Augusta, Georgia, 30912
Status
Recruiting
Address
Memorial Health University Medical Center
Savannah, Georgia, 31404
Status
Active, not recruiting
Address
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia, 31405
Status
Active, not recruiting
Address
Queen's Medical Center
Honolulu, Hawaii, 96813
Status
Active, not recruiting
Address
The Cancer Center of Hawaii-Liliha
Honolulu, Hawaii, 96817
Status
Recruiting
Address
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho, 83687
Status
Suspended
Address
Northwestern University
Chicago, Illinois, 60611
Status
Recruiting
Address
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, 60612
Status
Active, not recruiting
Address
Rush University Medical Center
Chicago, Illinois, 60612
Status
Active, not recruiting
Address
University of Illinois
Chicago, Illinois, 60612
Status
Recruiting
Address
Decatur Memorial Hospital
Decatur, Illinois, 62526
Status
Recruiting
Address
Crossroads Cancer Center
Effingham, Illinois, 62401
Status
Recruiting
Address
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, 60201
Status
Recruiting
Address
NorthShore University HealthSystem-Glenbrook Hospital
Glenview, Illinois, 60026
Status
Recruiting
Address
NorthShore University HealthSystem-Highland Park Hospital
Highland Park, Illinois, 60035
Status
Recruiting
Address
HSHS Saint Elizabeth's Hospital
O'Fallon, Illinois, 62269
Status
Active, not recruiting
Address
Advocate Christ Medical Center
Oak Lawn, Illinois, 60453-2699
Status
Recruiting
Address
OSF Saint Francis Radiation Oncology at Peoria Cancer Center
Peoria, Illinois, 61615
Status
Recruiting
Address
OSF Saint Francis Medical Center
Peoria, Illinois, 61637
Status
Recruiting
Address
UW Health Carbone Cancer Center Rockford
Rockford, Illinois, 61114
Status
Recruiting
Address
Springfield Memorial Hospital
Springfield, Illinois, 62781
Status
Recruiting
Address
Carle Cancer Center
Urbana, Illinois, 61801
Status
Active, not recruiting
Address
Ascension Saint Vincent Anderson
Anderson, Indiana, 46016
Status
Active, not recruiting
Address
Elkhart General Hospital
Elkhart, Indiana, 46515
Status
Suspended
Address
Radiation Oncology Associates PC
Fort Wayne, Indiana, 46804
Status
Active, not recruiting
Address
Parkview Hospital Randallia
Fort Wayne, Indiana, 46805
Status
Active, not recruiting
Address
Parkview Regional Medical Center
Fort Wayne, Indiana, 46845
Status
Active, not recruiting
Address
Goshen Center for Cancer Care
Goshen, Indiana, 46526
Status
Suspended
Address
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202
Status
Suspended
Address
IU Health Methodist Hospital
Indianapolis, Indiana, 46202
Status
Active, not recruiting
Address
IU Health Central Indiana Cancer Centers-East
Indianapolis, Indiana, 46219
Status
Active, not recruiting
Address
Michiana Hematology Oncology PC-Mishawaka
Mishawaka, Indiana, 46545
Status
Active, not recruiting
Address
Memorial Hospital of South Bend
South Bend, Indiana, 46601
Status
Active, not recruiting
Address
McFarland Clinic - Ames
Ames, Iowa, 50010
Status
Active, not recruiting
Address
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Status
Recruiting
Address
University of Kansas Cancer Center
Kansas City, Kansas, 66160
Status
Recruiting
Address
The University of Kansas Cancer Center - Olathe
Olathe, Kansas, 66061
Status
Recruiting
Address
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, 66210
Status
Recruiting
Address
Salina Regional Health Center
Salina, Kansas, 67401
Status
Active, not recruiting
Address
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536
Status
Suspended
Address
The James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky, 40202
Status
Recruiting
Address
UofL Health Medical Center Northeast
Louisville, Kentucky, 40245
Status
Active, not recruiting
Address
Tulane University School of Medicine
New Orleans, Louisiana, 70112
Status
Recruiting
Address
University Medical Center New Orleans
New Orleans, Louisiana, 70112
Status
Active, not recruiting
Address
Ochsner Medical Center Jefferson
New Orleans, Louisiana, 70121
Status
Recruiting
Address
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, 21201
Status
Recruiting
Address
Greater Baltimore Medical Center
Baltimore, Maryland, 21204
Status
Recruiting
Address
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287
Status
Recruiting
Address
UM Upper Chesapeake Medical Center
Bel Air, Maryland, 21014
Status
Recruiting
Address
Central Maryland Radiation Oncology in Howard County
Columbia, Maryland, 21044
Status
Recruiting
Address
UM Baltimore Washington Medical Center/Tate Cancer Center
Glen Burnie, Maryland, 21061
Status
Active, not recruiting
Address
Holy Cross Hospital
Silver Spring, Maryland, 20910
Status
Recruiting
Address
Boston Medical Center
Boston, Massachusetts, 02118
Status
Recruiting
Address
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor, Michigan, 48106
Status
Active, not recruiting
Address
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109
Status
Recruiting
Address
Trinity Health Medical Center - Brighton
Brighton, Michigan, 48114
Status
Active, not recruiting
Address
University of Michigan - Brighton Center for Specialty Care
Brighton, Michigan, 48116
Status
Recruiting
Address
Henry Ford Cancer Institute-Downriver
Brownstown, Michigan, 48183
Status
Recruiting
Address
Henry Ford Macomb Hospital-Clinton Township
Clinton Township, Michigan, 48038
Status
Recruiting
Address
Henry Ford Hospital
Detroit, Michigan, 48202
Status
Recruiting
Address
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Grand Rapids, Michigan, 49503
Status
Recruiting
Address
Allegiance Health
Jackson, Michigan, 49201
Status
Recruiting
Address
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Status
Recruiting
Address
University of Michigan Health - Sparrow Lansing
Lansing, Michigan, 48912
Status
Recruiting
Address
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan, 48154
Status
Recruiting
Address
Henry Ford Medical Center-Columbus
Novi, Michigan, 48377
Status
Active, not recruiting
Address
Corewell Health William Beaumont University Hospital
Royal Oak, Michigan, 48073
Status
Recruiting
Address
MyMichigan Medical Center Saginaw
Saginaw, Michigan, 48601
Status
Active, not recruiting
Address
Corewell Health Beaumont Troy Hospital
Troy, Michigan, 48085
Status
Recruiting
Address
Henry Ford West Bloomfield Hospital
West Bloomfield, Michigan, 48322
Status
Recruiting
Address
University of Michigan Health - West
Wyoming, Michigan, 49519
Status
Recruiting
Address
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, 56601
Status
Recruiting
Address
Minnesota Oncology - Burnsville
Burnsville, Minnesota, 55337
Status
Recruiting
Address
Miller-Dwan Hospital
Duluth, Minnesota, 55805
Status
Recruiting
Address
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Status
Suspended
Address
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Status
Recruiting
Address
Coborn Cancer Center at Saint Cloud Hospital
Saint Cloud, Minnesota, 56303
Status
Suspended
Address
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Status
Recruiting
Address
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Status
Active, not recruiting
Address
MU Health - University Hospital/Ellis Fischel Cancer Center
Columbia, Missouri, 65212
Status
Active, not recruiting
Address
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141
Status
Suspended
Address
North Kansas City Hospital
Kansas City, Missouri, 64116
Status
Suspended
Address
The University of Kansas Cancer Center-South
Kansas City, Missouri, 64131
Status
Recruiting
Address
University of Kansas Cancer Center - North
Kansas City, Missouri, 64154
Status
Recruiting
Address
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064
Status
Recruiting
Address
Phelps Health Delbert Day Cancer Institute
Rolla, Missouri, 65401
Status
Active, not recruiting
Address
Washington University School of Medicine
Saint Louis, Missouri, 63110
Status
Active, not recruiting
Address
Siteman Cancer Center-South County
Saint Louis, Missouri, 63129
Status
Recruiting
Address
Missouri Baptist Medical Center
Saint Louis, Missouri, 63131
Status
Recruiting
Address
Mercy Hospital Saint Louis
Saint Louis, Missouri, 63141
Status
Active, not recruiting
Address
Siteman Cancer Center at Saint Peters Hospital
Saint Peters, Missouri, 63376
Status
Recruiting
Address
Mercy Hospital Springfield
Springfield, Missouri, 65804
Status
Recruiting
Address
CoxHealth South Hospital
Springfield, Missouri, 65807
Status
Recruiting
Address
CHI Health Good Samaritan
Kearney, Nebraska, 68847
Status
Active, not recruiting
Address
Nebraska Methodist Hospital
Omaha, Nebraska, 68114
Status
Recruiting
Address
Alegent Health Bergan Mercy Medical Center
Omaha, Nebraska, 68124
Status
Recruiting
Address
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, New Hampshire, 03756
Status
Active, not recruiting
Address
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920
Status
Recruiting
Address
The Cancer Institute of New Jersey Hamilton
Hamilton, New Jersey, 08690
Status
Recruiting
Address
Saint Barnabas Medical Center
Livingston, New Jersey, 07039
Status
Recruiting
Address
Monmouth Medical Center
Long Branch, New Jersey, 07740
Status
Active, not recruiting
Address
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748
Status
Active, not recruiting
Address
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645
Status
Active, not recruiting
Address
Virtua Memorial
Mount Holly, New Jersey, 08060
Status
Recruiting
Address
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
Status
Recruiting
Address
Rutgers New Jersey Medical School
Newark, New Jersey, 07101
Status
Suspended
Address
Sparta Cancer Treatment Center
Sparta, New Jersey, 07871
Status
Recruiting
Address
Community Medical Center
Toms River, New Jersey, 08755
Status
Active, not recruiting
Address
Virtua Voorhees
Voorhees, New Jersey, 08043
Status
Recruiting
Address
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87106
Status
Recruiting
Address
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, 87109
Status
Active, not recruiting
Address
South Shore University Hospital
Bay Shore, New York, 11706
Status
Recruiting
Address
Montefiore Medical Center-Einstein Campus
Bronx, New York, 10461
Status
Recruiting
Address
Montefiore Medical Center - Moses Campus
Bronx, New York, 10467
Status
Suspended
Address
New York-Presbyterian/Brooklyn Methodist Hospital
Brooklyn, New York, 11215
Status
Recruiting
Address
NYU Langone Hospital - Brooklyn
Brooklyn, New York, 11220
Status
Recruiting
Address
Roswell Park Cancer Institute
Buffalo, New York, 14263
Status
Recruiting
Address
Sands Cancer Center
Canandaigua, New York, 14424
Status
Active, not recruiting
Address
Memorial Sloan Kettering Commack
Commack, New York, 11725
Status
Suspended
Address
Arnot Ogden Medical Center/Falck Cancer Center
Elmira, New York, 14905
Status
Active, not recruiting
Address
Memorial Sloan Kettering Westchester
Harrison, New York, 10604
Status
Active, not recruiting
Address
Northwell Health/Center for Advanced Medicine
Lake Success, New York, 11042
Status
Recruiting
Address
NYU Langone Hospital - Long Island
Mineola, New York, 11501
Status
Active, not recruiting
Address
Mount Sinai Union Square
New York, New York, 10003
Status
Recruiting
Address
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016
Status
Active, not recruiting
Address
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
Status
Active, not recruiting
Address
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Status
Recruiting
Address
Wilmot Cancer Institute Radiation Oncology at Greece
Rochester, New York, 14606
Status
Recruiting
Address
Highland Hospital
Rochester, New York, 14620
Status
Recruiting
Address
University of Rochester
Rochester, New York, 14642
Status
Active, not recruiting
Address
Memorial Sloan Kettering Sleepy Hollow
Sleepy Hollow, New York, 10591
Status
Recruiting
Address
State University of New York Upstate Medical University
Syracuse, New York, 13210
Status
Active, not recruiting
Address
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553
Status
Recruiting
Address
Atrium Health Stanly/LCI-Albemarle
Albemarle, North Carolina, 28002
Status
Active, not recruiting
Address
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599
Status
Recruiting
Address
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, 28203
Status
Recruiting
Address
Atrium Health Pineville/LCI-Pineville
Charlotte, North Carolina, 28210
Status
Recruiting
Address
Atrium Health University City/LCI-University
Charlotte, North Carolina, 28262
Status
Recruiting
Address
Atrium Health Cabarrus/LCI-Concord
Concord, North Carolina, 28025
Status
Suspended
Address
East Carolina University
Greenville, North Carolina, 27834
Status
Recruiting
Address
ECU Health Oncology Kinston
Kinston, North Carolina, 28501
Status
Recruiting
Address
Atrium Health Union/LCI-Union
Monroe, North Carolina, 28112
Status
Active, not recruiting
Address
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157
Status
Recruiting
Address
Sanford Bismarck Medical Center
Bismarck, North Dakota, 58501
Status
Recruiting
Address
Sanford Roger Maris Cancer Center
Fargo, North Dakota, 58122
Status
Active, not recruiting
Address
Summa Health System - Akron Campus
Akron, Ohio, 44304
Status
Active, not recruiting
Address
Cleveland Clinic Akron General
Akron, Ohio, 44307
Status
Recruiting
Address
UH Seidman Cancer Center at UH Avon Health Center
Avon, Ohio, 44011
Status
Active, not recruiting
Address
Summa Health System - Barberton Campus
Barberton, Ohio, 44203
Status
Recruiting
Address
UHHS-Chagrin Highlands Medical Center
Beachwood, Ohio, 44122
Status
Recruiting
Address
Geauga Hospital
Chardon, Ohio, 44024
Status
Recruiting
Address
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Status
Suspended
Address
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio, 45219
Status
Recruiting
Address
Case Western Reserve University
Cleveland, Ohio, 44106
Status
Recruiting
Address
MetroHealth Medical Center
Cleveland, Ohio, 44109
Status
Active, not recruiting
Address
Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio, 44111
Status
Recruiting
Address
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Status
Recruiting
Address
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Status
Suspended
Address
Mercy Cancer Center-Elyria
Elyria, Ohio, 44035
Status
Suspended
Address
Cleveland Clinic Cancer Center Independence
Independence, Ohio, 44131
Status
Suspended
Address
OhioHealth Mansfield Hospital
Mansfield, Ohio, 44903
Status
Active, not recruiting
Address
Hillcrest Hospital Cancer Center
Mayfield Heights, Ohio, 44124
Status
Active, not recruiting
Address
Summa Health Medina Medical Center
Medina, Ohio, 44256
Status
Recruiting
Address
UH Seidman Cancer Center at Lake Health Mentor Campus
Mentor, Ohio, 44060
Status
Recruiting
Address
UH Seidman Cancer Center at Southwest General Hospital
Middleburg Heights, Ohio, 44130
Status
Recruiting
Address
University Hospitals Parma Medical Center
Parma, Ohio, 44129
Status
Recruiting
Address
Southern Ohio Medical Center
Portsmouth, Ohio, 45662
Status
Recruiting
Address
University Hospitals Portage Medical Center
Ravenna, Ohio, 44266
Status
Active, not recruiting
Address
North Coast Cancer Care
Sandusky, Ohio, 44870
Status
Recruiting
Address
UH Seidman Cancer Center at Firelands Regional Medical Center
Sandusky, Ohio, 44870
Status
Recruiting
Address
Cleveland Clinic Cancer Center Strongsville
Strongsville, Ohio, 44136
Status
Suspended
Address
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio, 45069
Status
Recruiting
Address
UHHS-Westlake Medical Center
Westlake, Ohio, 44145
Status
Recruiting
Address
Cleveland Clinic Wooster Family Health and Surgery Center
Wooster, Ohio, 44691
Status
Recruiting
Address
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Status
Recruiting
Address
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Status
Recruiting
Address
Providence Portland Medical Center
Portland, Oregon, 97213
Status
Recruiting
Address
Providence Saint Vincent Medical Center
Portland, Oregon, 97225
Status
Recruiting
Address
UPMC Altoona
Altoona, Pennsylvania, 16601
Status
Recruiting
Address
UPMC-Heritage Valley Health System Beaver
Beaver, Pennsylvania, 15009
Status
Recruiting
Address
Carlisle Regional Cancer Center
Carlisle, Pennsylvania, 17015
Status
Recruiting
Address
UPMC Hillman Cancer Center Erie
Erie, Pennsylvania, 16505
Status
Recruiting
Address
UPMC Cancer Center at UPMC Horizon
Farrell, Pennsylvania, 16121
Status
Recruiting
Address
UPMC Cancer Centers - Arnold Palmer Pavilion
Greensburg, Pennsylvania, 15601
Status
Recruiting
Address
UPMC Pinnacle Cancer Center/Community Osteopathic Campus
Harrisburg, Pennsylvania, 17109
Status
Active, not recruiting
Address
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
Status
Recruiting
Address
IRMC Cancer Center
Indiana, Pennsylvania, 15701
Status
Recruiting
Address
UPMC-Johnstown/John P. Murtha Regional Cancer Center
Johnstown, Pennsylvania, 15901
Status
Recruiting
Address
UPMC Cancer Center at UPMC McKeesport
McKeesport, Pennsylvania, 15132
Status
Recruiting
Address
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
Mechanicsburg, Pennsylvania, 17050
Status
Recruiting
Address
UPMC Cancer Center - Monroeville
Monroeville, Pennsylvania, 15146
Status
Recruiting
Address
UPMC Hillman Cancer Center in Coraopolis
Moon, Pennsylvania, 15108
Status
Suspended
Address
UPMC Cancer Center-Natrona Heights
Natrona Heights, Pennsylvania, 15065
Status
Suspended
Address
UPMC Jameson
New Castle, Pennsylvania, 16105
Status
Recruiting
Address
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
Status
Recruiting
Address
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
Status
Recruiting
Address
Temple University Hospital
Philadelphia, Pennsylvania, 19140
Status
Recruiting
Address
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
Status
Recruiting
Address
UPMC-Magee Womens Hospital
Pittsburgh, Pennsylvania, 15213
Status
Recruiting
Address
UPMC-Saint Margaret
Pittsburgh, Pennsylvania, 15215
Status
Recruiting
Address
UPMC-Shadyside Hospital
Pittsburgh, Pennsylvania, 15232
Status
Suspended
Address
UPMC Jefferson Regional Radiation Oncology
Pittsburgh, Pennsylvania, 15236
Status
Recruiting
Address
UPMC-Passavant Hospital
Pittsburgh, Pennsylvania, 15237
Status
Recruiting
Address
UPMC-Saint Clair Hospital Cancer Center
Pittsburgh, Pennsylvania, 15243
Status
Recruiting
Address
UPMC Cancer Center at UPMC Northwest
Seneca, Pennsylvania, 16346
Status
Recruiting
Address
UPMC Uniontown Hospital Radiation Oncology
Uniontown, Pennsylvania, 15401
Status
Recruiting
Address
UPMC Washington Hospital Radiation Oncology
Washington, Pennsylvania, 15301
Status
Suspended
Address
Reading Hospital
West Reading, Pennsylvania, 19611
Status
Recruiting
Address
Wexford Health and Wellness Pavilion
Wexford, Pennsylvania, 15090
Status
Suspended
Address
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Status
Active, not recruiting
Address
Saint Joseph's/Candler - Bluffton Campus
Bluffton, South Carolina, 29910
Status
Suspended
Address
Prisma Health Cancer Institute - Spartanburg
Boiling Springs, South Carolina, 29316
Status
Recruiting
Address
Medical University of South Carolina
Charleston, South Carolina, 29425
Status
Recruiting
Address
Prisma Health Cancer Institute - Faris
Greenville, South Carolina, 29605
Status
Recruiting
Address
Prisma Health Cancer Institute - Eastside
Greenville, South Carolina, 29615
Status
Recruiting
Address
Prisma Health Cancer Institute - Greer
Greer, South Carolina, 29650
Status
Recruiting
Address
Gibbs Cancer Center-Pelham
Greer, South Carolina, 29651
Status
Recruiting
Address
Rock Hill Radiation Therapy Center
Rock Hill, South Carolina, 29730
Status
Recruiting
Address
Prisma Health Cancer Institute - Seneca
Seneca, South Carolina, 29672
Status
Recruiting
Address
Spartanburg Medical Center
Spartanburg, South Carolina, 29303
Status
Active, not recruiting
Address
Rapid City Regional Hospital
Rapid City, South Dakota, 57701
Status
Recruiting
Address
Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota, 57117-5134
Status
Active, not recruiting
Address
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232
Status
Suspended
Address
MD Anderson in The Woodlands
Conroe, Texas, 77384
Status
Active, not recruiting
Address
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390
Status
Active, not recruiting
Address
University of Texas Medical Branch
Galveston, Texas, 77555-0565
Status
Suspended
Address
M D Anderson Cancer Center
Houston, Texas, 77030
Status
Suspended
Address
MD Anderson West Houston
Houston, Texas, 77079
Status
Suspended
Address
MD Anderson League City
League City, Texas, 77573
Status
Active, not recruiting
Address
UTMB Cancer Center at Victory Lakes
League City, Texas, 77573
Status
Active, not recruiting
Address
Covenant Medical Center-Lakeside
Lubbock, Texas, 79410
Status
Suspended
Address
MD Anderson in Sugar Land
Sugar Land, Texas, 77478
Status
Active, not recruiting
Address
Intermountain Medical Center
Murray, Utah, 84107
Status
Active, not recruiting
Address
Saint George Regional Medical Center
Saint George, Utah, 84770
Status
Active, not recruiting
Address
Utah Cancer Specialists-Salt Lake City
Salt Lake City, Utah, 84106
Status
Recruiting
Address
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112
Status
Recruiting
Address
Dartmouth Cancer Center - North
Saint Johnsbury, Vermont, 05819
Status
Active, not recruiting
Address
Inova Fairfax Hospital
Falls Church, Virginia, 22042
Status
Active, not recruiting
Address
Sentara Cancer Institute at Sentara CarePlex Hospital
Hampton, Virginia, 23666
Status
Active, not recruiting
Address
Sentara Norfolk General Hospital
Norfolk, Virginia, 23507
Status
Active, not recruiting
Address
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, 23298
Status
Active, not recruiting
Address
Sentara Virginia Beach General Hospital
Virginia Beach, Virginia, 23454
Status
Suspended
Address
Saint Francis Hospital
Federal Way, Washington, 98003
Status
Suspended
Address
Tri-Cities Cancer Center
Kennewick, Washington, 99336
Status
Recruiting
Address
PeaceHealth Saint John Medical Center
Longview, Washington, 98632
Status
Recruiting
Address
Skagit Regional Health Cancer Care Center
Mount Vernon, Washington, 98274
Status
Recruiting
Address
University of Washington Medical Center - Montlake
Seattle, Washington, 98195
Status
Suspended
Address
Spokane Valley Cancer Center-Mayfair
Spokane, Washington, 99208
Status
Suspended
Address
Spokane Valley Cancer Center-Mission
Spokane, Washington, 99216
Status
Recruiting
Address
Wenatchee Valley Hospital and Clinics
Wenatchee, Washington, 98801
Status
Recruiting
Address
West Virginia University Healthcare
Morgantown, West Virginia, 26506
Status
Recruiting
Address
Camden Clark Medical Center
Parkersburg, West Virginia, 26101
Status
Recruiting
Address
Wheeling Hospital/Schiffler Cancer Center
Wheeling, West Virginia, 26003
Status
Recruiting
Address
Langlade Hospital and Cancer Center
Antigo, Wisconsin, 54409
Status
Recruiting
Address
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Status
Recruiting
Address
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
Status
Recruiting
Address
University of Wisconsin Carbone Cancer Center - Johnson Creek
Johnson Creek, Wisconsin, 53038
Status
Recruiting
Address
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Status
Withdrawn
Address
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin, 54601
Status
Recruiting
Address
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792
Status
Active, not recruiting
Address
Bay Area Medical Center
Marinette, Wisconsin, 54143
Status
Active, not recruiting
Address
Marshfield Medical Center
Marshfield, Wisconsin, 54449
Status
Suspended
Address
Froedtert Menomonee Falls Hospital
Menomonee Falls, Wisconsin, 53051
Status
Recruiting
Address
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Status
Active, not recruiting
Address
Marshfield Medical Center - Minocqua
Minocqua, Wisconsin, 54548
Status
Recruiting
Address
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
Status
Suspended
Address
Drexel Town Square Health Center
Oak Creek, Wisconsin, 53154
Status
Recruiting
Address
Aspirus Cancer Care - James Beck Cancer Center
Rhinelander, Wisconsin, 54501
Status
Active, not recruiting
Address
Aspirus Cancer Care - Stevens Point
Stevens Point, Wisconsin, 54481
Status
Recruiting
Address
Saint Vincent Hospital Cancer Center at Sturgeon Bay
Sturgeon Bay, Wisconsin, 54235-1495
Status
Recruiting
Address
Aspirus Regional Cancer Center
Wausau, Wisconsin, 54401
Status
Suspended
Address
Froedtert West Bend Hospital/Kraemer Cancer Center
West Bend, Wisconsin, 53095
Status
Recruiting
Address
Aspirus Cancer Care - Wisconsin Rapids
Wisconsin Rapids, Wisconsin, 54494
International Sites
Status
Recruiting
Address
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Status
Suspended
Address
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1
Status
Active, not recruiting
Address
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4
Status
Active, not recruiting
Address
Chinese University of Hong Kong-Prince of Wales Hospital
Shatin, ,
